Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Capital Expenditures (2018 - 2025)

UroGen Pharma (URGN) has disclosed Capital Expenditures for 8 consecutive years, with $17000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 85.22% year-over-year to $17000.0, compared with a TTM value of $289000.0 through Dec 2025, down 2.03%, and an annual FY2025 reading of $289000.0, down 2.03% over the prior year.
  • Capital Expenditures was $17000.0 for Q4 2025 at UroGen Pharma, down from $87000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $287000.0 in Q1 2021 and bottomed at $13000.0 in Q4 2022.
  • Average Capital Expenditures over 5 years is $93894.7, with a median of $84000.0 recorded in 2024.
  • The sharpest move saw Capital Expenditures plummeted 93.56% in 2022, then soared 460.0% in 2024.
  • Year by year, Capital Expenditures stood at $202000.0 in 2021, then tumbled by 93.56% to $13000.0 in 2022, then surged by 330.77% to $56000.0 in 2023, then skyrocketed by 105.36% to $115000.0 in 2024, then plummeted by 85.22% to $17000.0 in 2025.
  • Business Quant data shows Capital Expenditures for URGN at $17000.0 in Q4 2025, $87000.0 in Q3 2025, and $141000.0 in Q2 2025.